환자 혈액 관리 시장 : 시장 점유율 분석, 업계 동향 및 통계, 성장 예측(2026-2031년)

According to Mordor Intelligence, the patient blood management market size is projected to be USD 16.54 billion in 2025, USD 17.67 billion in 2026, and reach USD 24.60 billion by 2031, growing at a CAGR of 6.84% from 2026 to 2031.

This report is Segmented by Product Type (Instrument, Accessories, Reagent and Kits, Software), End User (Hospitals & Clinics, Blood Banks, Diagnostic Centers & Laboratories, Others), and Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America). The Market Forecasts are Provided in Terms of Value (USD).

Global Patient Blood Management Market Trends and Insights

Rising Elective Surgical Volumes and Blood Conservation Priorities

Elective surgeries have surpassed pre-pandemic levels in many high-income healthcare systems, boosting demand in the patient blood management market. A 2025 study revealed that each unit of red blood cells used in elective non-cardiac surgeries added an average direct hospital cost of USD 491, representing 5.2% of the median total episode cost. Hospitals are increasingly leveraging blood management teams as cost-control units, influencing capital approvals for monitoring and salvage systems. The 2024 EACTS and EACTAIC guidelines elevated point-of-care viscoelastic testing algorithms to essential tools in cardiac centers, driving demand for thromboelastography and ROTEM platforms and enhancing instrument utilization and consumable demand.

Preoperative Anemia Screening and Treatment Expands PBM Adoption

Preoperative anemia, affecting 25% to 35% of surgical patients, remains underdiagnosed and untreated, creating growth potential for the patient blood management market. Untreated anemia increases perioperative risks and reliance on transfusions. A 2025 study of 1,294 colorectal cancer patients showed intravenous iron protocols reduced postoperative transfusion rates to 10.7%, with compliance improving over time. Hospitals are shifting demand upstream to outpatient screening kits, iron therapy, and related accessories, boosting reagent and kit demand. AABB certification frameworks are helping integrate anemia screening into institutional workflows.

High Upfront Cost of PBM Devices, Software, and Training

Capital expenditures remain a key barrier to expanding patient blood management (PBM), particularly for district and smaller community hospitals with limited budgets. In Germany, only 70 out of 2,000 hospitals participated in the national PBM network, reflecting financial and administrative challenges. A 2024 Oxford University study found that just 14.2% of NHS England hospitals implemented advanced clinical decision support for transfusion management, with financial constraints and limited senior engagement as major obstacles. Multi-year contracts bundled with instrument placements often obscure long-term costs, leading to underestimated consumable expenses and delayed rollouts. WHO guidance from 2025 suggests cost-effective scale-up strategies, but adoption timelines remain lengthy for many facilities.

Other drivers and restraints analyzed in the detailed report include:

1. Value-Based Care and Transfusion Stewardship Pressure Hospitals to Standardize
2. Expansion of Point-of-Care Testing for Rapid Blood Management Decisions
3. Workflow Resistance Among Clinicians and Transfusion Committees

For complete list of drivers and restraints, kindly check the Table Of Contents.

Segment Analysis

In 2025, instruments accounted for 59.6% of the patient blood management market, driven by a decade of investments in automated blood analyzers, cell salvage systems, and viscoelastic testing platforms. Increased utilization of these systems is significantly enhancing reagent demand. Reagents and kits are projected to grow at an 8.76% CAGR through 2031, supported by rising anemia screenings, donor panels, and coagulation tests. Roche's 2026 launch of the cobas MPX-E assay highlights the market's shift toward workflow consolidation and higher reagent use per sample.

Software remains the smallest revenue segment in the patient blood management market, while accessories benefit from increased blood handling, separation, and apheresis activities in blood banks and hospitals. Accessories like blood bags, syringes, and vials see steady demand, particularly in Asia-Pacific and Latin America. Despite its smaller revenue base, software plays a strategic role in influencing instrument usage and adherence to transfusion protocols. Hospitals are adopting software for oversight, auditability, and aligning policies with daily transfusion practices.

Complete Report Scope:

• By Product Type
  • Instrument
  • Accessories
  • Reagent and Kits
  • Softwares
• By End User
  • Hospitals & Clinics
  • Blood Banks
  • Diagnostic Centers & Laboratories
  • Others
• By Geography
  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
    • Rest of Asia-Pacific
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa
  • South America
    • Brazil
    • Argentina
    • Rest of South America

Geography Analysis

In 2025, North America accounted for 39.4% of the patient blood management market, driven by advanced healthcare infrastructure, high surgical volumes, and established stewardship governance. The United States leads regional demand due to a reimbursement framework linking hospital performance to transfusion safety and efficiency outcomes. PBM program adoption in North America reached 50.2% in 2025, up from 37.8% in 2013, with 80.2% of institutions promoting single-unit transfusion strategies. Canada supports market stability by aligning with U.S. clinical practices, while Mexico shows growing demand as PBM adoption expands. The region benefits from EHR-integrated decision support, increasing vendor retention in hospital workflows.

Europe remains a key player in the patient blood management market, with Germany, the United Kingdom, France, Italy, and Spain as major demand centers. Germany highlights significant potential, with only 70 of its 2,000 hospitals part of the national PBM network, leaving room for expansion. The 2024 cardiac surgery guidelines are formalizing viscoelastic testing across European cardiac centers, supporting structured replacement cycles for TEG and ROTEM platforms. Reimbursement structures vary, but markets like Germany show clear alignment between PBM outcomes, reduced complications, and improved hospital performance.

Asia-Pacific is projected to achieve the fastest growth in the patient blood management market, with a 7.23% CAGR through 2031. China drives this growth with revised regulations mandating patient-centered blood management protocols, preoperative anemia management, and autologous transfusion promotion. Its National Blood Management Information System is enhancing hospital demand for blood bank information systems and related software. India, Japan, Australia, and South Korea are scaling adoption due to aging populations and rising surgical volumes, while the GCC and parts of South America are gradually advancing blood bank automation.

1. Abbott Laboratories
2. B. Braun
3. Baxter
4. bioMerieux
5. Cerus
6. CSL Behring
7. Danaher
8. Roche
9. Fresenius SE and Co. KGaA
10. Grifols
11. Haemonetics
12. LivaNova
13. Masimo
14. Medtronic
15. Ortho Clinical Diagnostics, LLC
16. QIAGEN
17. Siemens Healthineers
18. Sysmex
19. Terumo
20. Werfen, S.A.

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support

TABLE OF CONTENTS

1 Introduction

• 1.1 Study Assumptions & Market Definition
• 1.2 Scope of the Study

2 Research Methodology

3 Executive Summary

4 Market Landscape

• 4.1 Market Overview
• 4.2 Market Drivers
  • 4.2.1 Rising Elective Surgical Volumes and Blood Conservation Priorities
  • 4.2.2 Preoperative Anemia Screening and Treatment Expands PBM Adoption
  • 4.2.3 Value-Based Care and Transfusion Stewardship Pressure Hospitals to Standardize PBM
  • 4.2.4 Expansion of Point-of-Care Testing for Rapid Blood Management Decisions
  • 4.2.5 AI-Enabled Transfusion Decision Support and Analytics Improve Compliance
  • 4.2.6 Reimbursement and Quality Reporting Incentives Favor Lower Transfusion Use
• 4.3 Market Restraints
  • 4.3.1 High Upfront Cost of PBM Devices, Software, and Training
  • 4.3.2 Workflow Resistance Among Clinicians and Transfusion Committees
  • 4.3.3 Uneven Clinical Evidence Adoption Across Specialty and Resource-Constrained Facilities
  • 4.3.4 Fragmented Procurement and Lack of Interoperability Across Hospital IT Systems
• 4.4 Value / Supply-Chain Analysis
• 4.5 Regulatory Landscape
• 4.6 Technological Outlook
• 4.7 Porter's Five Forces Analysis
  • 4.7.1 Threat of New Entrants
  • 4.7.2 Bargaining Power of Suppliers
  • 4.7.3 Bargaining Power of Buyers
  • 4.7.4 Threat of Substitutes
  • 4.7.5 Industry Rivalry

5 Market Size & Growth Forecasts (Value, USD)

• 5.1 By Product Type
  • 5.1.1 Instrument
  • 5.1.2 Accessories
  • 5.1.3 Reagent and Kits
  • 5.1.4 Softwares
• 5.2 By End User
  • 5.2.1 Hospitals & Clinics
  • 5.2.2 Blood Banks
  • 5.2.3 Diagnostic Centers & Laboratories
  • 5.2.4 Others
• 5.3 By Geography
  • 5.3.1 North America
    • 5.3.1.1 United States
    • 5.3.1.2 Canada
    • 5.3.1.3 Mexico
  • 5.3.2 Europe
    • 5.3.2.1 Germany
    • 5.3.2.2 United Kingdom
    • 5.3.2.3 France
    • 5.3.2.4 Italy
    • 5.3.2.5 Spain
    • 5.3.2.6 Rest of Europe
  • 5.3.3 Asia-Pacific
    • 5.3.3.1 China
    • 5.3.3.2 India
    • 5.3.3.3 Japan
    • 5.3.3.4 Australia
    • 5.3.3.5 South Korea
    • 5.3.3.6 Rest of Asia-Pacific
  • 5.3.4 Middle East and Africa
    • 5.3.4.1 GCC
    • 5.3.4.2 South Africa
    • 5.3.4.3 Rest of Middle East and Africa
  • 5.3.5 South America
    • 5.3.5.1 Brazil
    • 5.3.5.2 Argentina
    • 5.3.5.3 Rest of South America

6 Competitive Landscape

• 6.1 Market Concentration
• 6.2 Market Share Analysis
• 6.3 Company Profiles (includes Global level Overview, Market level overview, Core Segments, Financials as available, Strategic Information, Market Rank/Share for key companies, Products & Services, and Recent Developments)
  • 6.3.1 Abbott Laboratories
  • 6.3.2 B. Braun SE
  • 6.3.3 Baxter International Inc.
  • 6.3.4 bioMerieux SA
  • 6.3.5 Cerus Corporation
  • 6.3.6 CSL Limited
  • 6.3.7 Danaher Corporation
  • 6.3.8 F. Hoffmann-La Roche AG
  • 6.3.9 Fresenius SE and Co. KGaA
  • 6.3.10 Grifols, S.A.
  • 6.3.11 Haemonetics Corporation
  • 6.3.12 LivaNova PLC
  • 6.3.13 Masimo Corporation
  • 6.3.14 Medtronic plc
  • 6.3.15 Ortho Clinical Diagnostics, LLC
  • 6.3.16 QIAGEN N.V.
  • 6.3.17 Siemens Healthineers AG
  • 6.3.18 Sysmex Corporation
  • 6.3.19 Terumo Corporation
  • 6.3.20 Werfen, S.A.

7 Market Opportunities & Future Outlook

• 7.1 White-space & Unmet-need Assessment